Skip to main content
Premium Trial:

Request an Annual Quote

StemCells to Acquire Stem Cell Sciences for $4.8M

NEW YORK (GenomeWeb News) – StemCells has inked a definitive agreement to acquire Stem Cell Sciences in a deal worth around $4.8 million.

The transaction will provide StemCells, which is focused on developing tissue-derived cellular products for therapeutic uses, with cell-based drug discovery technologies. Among the products StemCells gains through the deal are automated systems for production and manipulation of stem and progenitor cells, gene insertion technology for drug screening and for applications in cell and gene therapy, the SC Proven media formulation and reagent business, and SCS' licensing deals with firms, such as Merck and Millipore.

Palo Alto, Calif.-based StemCells will pay SCS 2.65 million shares of its common stock, worth around $4.1 million based on its Friday closing price of $1.56 on the Nasdaq. In addition, StemCells will provide SCS with $715,000 in cash as a loan for working capital purposes. StemCells said that upon completion of the acquisition it will waive certain loan obligations of SCS to repay the $715,000.

The total number of shares delivered to SCS will depend on the acquired subsidiaries of SCS having at least an agreed-upon target amount of working capital. A portion of the shares will be held in escrow for release in 12 months, said StemCells.

"This proposed acquisition will combine three distinct stem cell platforms, adult, embryonic and iPS cells, for both therapeutic and drug discovery applications, and will position StemCells to diversify and pursue near-term commercialization opportunities while continuing to develop our cell-based therapeutic products," StemCells President and CEO Martin McGlynn said in a statement.

The firms said that members of the SCS board and other significant stockholders representing more than 30 percent of SCS' outstanding shares have agreed to vote in favor of the deal, which is expected to close in two months. Approval by StemCells' shareholders is not required.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.